Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder:: observational follow-up study

被引:286
|
作者
Tiihonen, Jari [1 ]
Wahlbeck, Kristian
Lonnqvist, Jouko
Klaukka, Timo
Ioannidis, John P. A.
Volavka, Jan
Haukka, Jari
机构
[1] Univ Kuopio, Niuvanniemi Hosp, Dept Forens Psychiat, FIN-70240 Kuopio, Finland
[2] Natl Res & Dev Ctr Welf & Hlth STAKES, Helsinki, Finland
[3] Natl Publ Hlth Inst, Dept Mental Hlth & Alcohol Res, Helsinki, Finland
[4] Social Insurance Inst, Helsinki, Finland
[5] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin Trials & Evidence Based Med Unit, GR-45110 Ioannina, Greece
[6] NYU, New York, NY USA
来源
BRITISH MEDICAL JOURNAL | 2006年 / 333卷 / 7561期
关键词
D O I
10.1136/bmj.38881.382755.2F
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To study the association between prescribed antipsychotic drugs and outcome in schizophrenia or schizoaffective disorder in the community. Design Prospective cohort study using national central registers. Setting Community care in Finland. Participants Nationwide cohort of 2230 consecutive adults hospitalised in Finland for the first time because of schizophrenia or schizoaffective disorder, January 1995 to December 2001. Main outcome measures Rates of discontinuation of drugs (all causes), rates of rehospitalisation, and mortality associated with monotherapy with the 10 most commonly used antipsychotic drugs. Multivariate models and propensity score methods were used to adjust estimates of effectiveness. Results Initial use of clozapine (adjusted relative risk 0.17, 95% confidence interval 0.10 to 0.29), perphenazine depot (0.24, 0.13 to 0.47), and olanzapine (0.35, 0.18 to 0.71) were associated with the lowest rates of discontinuation for any reason when compared with oral haloperidol. During an average follow-up of 3.6 years, 4640 cases of rehospitalisation were recorded. Current use of perphenazine depot (0.32, 0.22 to 0.49), olanzapine (0.54, 0.41 to 0.71), and clozapine (0.64, 0.48 to 0.85) were associated with the lowest risk of rehospitalisation. Use of haloperidol was associated with a poor outcome among women. Mortality was markedly raised in patients not taking antipsychotics (12.3, 6.0 to 24.1) and the risk of suicide was high (37.4, 5.1 to 276). Conclusions The effectiveness of first and second generation antipsychotics varies greatly in the community. Patients treated with perphenazine depot, clozapine, or olanzapine have a substantially lower risk of rehospitalisation or discontinuation (for any reason) of their initial treatment than do patients treated with haloperidol. Excess mortality is seen mostly in patients not using antipsychotic drugs.
引用
收藏
页码:224 / 227
页数:4
相关论文
共 50 条
  • [1] Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec
    Stip, Emmanuel
    Lachaine, Jean
    [J]. THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2018, 8 (11) : 287 - 301
  • [2] Weight gain in patients with schizophrenia and schizoaffective disorder under antipsychotic treatment: A three-year naturalistic follow-up study
    Yildiz, Mustafa
    [J]. KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2008, 18 : S43 - S49
  • [3] Nonadherence after hospital discharge in patients with schizophrenia or schizoaffective disorder: A six-month naturalistic follow-up study
    Vega, Dulcinea
    Acosta, Francisco J.
    Saavedra, Pedro
    [J]. COMPREHENSIVE PSYCHIATRY, 2021, 108
  • [4] Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up
    Taipale, Heidi
    Mehtala, Juha
    Tanskanen, Antti
    Tiihonen, Jari
    [J]. SCHIZOPHRENIA BULLETIN, 2018, 44 (06) : 1381 - 1387
  • [5] 20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia
    Tiihonen, Jari
    Tanskanen, Antti
    Taipale, Heidi
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2018, 175 (08): : 765 - 773
  • [6] Real-world outcome of antipsychotic treatment.: A 7-year follow-up study of a nationwide cohort of 3232 patients with first episode schizophrenia
    Tiihonen, J
    Wahlbeck, K
    Lönnqvist, J
    Klaukka, T
    Haukka, J
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S254 - S254
  • [7] 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia
    Tiihonen, Jari
    Tanskanen, Antti
    Taipale, Heidi
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 99 - 99
  • [8] Real-world effectiveness of antipsychotic treatments in 1011 acutely hospitalized patients with schizophrenia: A one-year follow-up study
    Hatta, Kotaro
    Katayama, Shigemasa
    Ishizuka, Takuya
    Sudo, Yasuhiko
    Nakamura, Mitsuru
    Hasegawa, Hana
    Imai, Atsushi
    Morikawa, Fumiyoshi
    Shimada, Tatsuhiro
    Misawa, Fuminari
    Ozaki, Shigeru
    Fujita, Kiyoshi
    Watanabe, Haruo
    Nakamura, Hiroyuki
    Sugiyama, Naoya
    [J]. ASIAN JOURNAL OF PSYCHIATRY, 2022, 67
  • [10] A prospective cohort study for metabolic measures during antipsychotic treatments in patients with schizophrenia and schizoaffective disorder: A cross-sectional analysis of baseline data
    Kusumi, Ichiro
    Arai, Yuki
    Honda, Minoru
    Ito, Koichi
    Matsubara, Shigehiro
    Matsuda, Yasuhiro
    Matsuda, Yukihiko
    Ohno, Kota
    Okubo, Ryo
    Sato, Norihiro
    Takekita, Yoshiteru
    Tochigi, Akihiko
    Tsuchiya, Kiyoshi
    Uemura, Keiichi
    Yamada, Jun
    Yamanaka, Hiroyoshi
    Yoshimura, Bunta
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 180 - 180